Roman S

Language: English
References: 11
Page: 541-543
PDF size: 108.56 Kb.

ABSTRACT

Occult hepatitis B infection (OBI) is the presence of hepatitis B virus (HBV) DNA in the liver and/or serum (< 200 IU/mL) in HBsAgnegative patients with or without serologic markers of previous viral exposure. The clinical significance of OBI is of concern in posttransfusional hepatitis B infection, hepatitis B reactivation, chronic liver disease and hepatocellular carcinoma (HCC). The diagnosis of OBI relays on the use of highly sensitive and specific laboratory techniques. Herein, comments derived from a study analyzing the frequency and characteristics of OBI in HCC Japanese patients are stated. While OBI and other causes of HCC have been highly studied in Asia and Europe, research in Latin America in these topics is limited. Several findings such as population risk groups with high prevalence of overt and OBI infection, HBV genotype F in Argentinean HCC patients, and the clinical impact of the foreign A-D genotypes suggest the need of further investigation. Additionally, alcoholism, obesity, NASH and type 2 diabetes may override the presence of OBI. Therefore, OBI diagnosis is essential. It is known that anti-HBc alone is a predictive signal of potential OBI and given the fluctuations of the HBV infection markers, testing for HBsAg and anti-HBc at baseline and follow-up is recommended. In conclusion, OBI and other causes involved in the epidemiology of HCC in Latin America are unexplored risk factors. Genome-based research is required to decipher the role of gene-environmental interactions associated with chronic liver disease. Novel algorithms to detect OBI supported by basic/applied/clinical research are also needed.

REFERENCES

1. Saffioti F, Raimondo G. What do we know about hepatitis B virus infection? In: AMPM (Atti della Accademia Peloritana dei Pericolaanti-Classe di Scienze Medico-Biologiche). Vol. 105(2): SD2, 2017, p 1-13. DOI:10.6092/1828-6550/ APMB.105.2.2017.SD2.

2. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.

3. Allain JP. Global epidemiology of occult HBV infection. Ann Blood 2017; 2: 7.

4. Muto J, Sugiyama M, Shirabe K, Mukaide M, Kirikae-Muto I, Ikegami T, Yoshizumi T, et al. Frequency and characteristics of occult Hepatitis B infection among hepatocellular carcinoma patients in Japan. Annals Hepatol 2018; 17: 596-603.

5. FH Pujol, Roman S, Panduro A, Navas MC, Lampe E. Hepatocellular Carcinoma in Latin America. In: Chemin I (Ed.). Hepatocellular Carcinoma: A Global Challenge. New York: Nova Science Publishers Inc; 2012, p. 55-68.

6. Morales-Romero J, Vargas G, García-Román R. Occult HBV Infection: A faceless enemy in liver cancer development. Viruses 2014; 6: 1590-611.

7. Roman S, Jose-Abrego J, Fierro NA, Escobedo-Melendez G, Ojeda-Granados C, Martinez-Lopez E, Panduro A. Hepatitis B virus infection in Latin America: A genomic medicine approach. World J Gastroenterol 2014: 20: 7181-96.

8. Panduro A, Maldonado-Gonzalez M, Fierro NA, Roman S. Distribution of HBV genotypes F and H in Mexico and Central America. Antivir Ther 2013; 18: 475-84.

9. Roman S, Fierro NA, Moreno-Luna LE, Panduro A. Hepatitis B virus genotype H and environmental factors associated to the low prevalence of hepatocellular carcinoma in Mexico. J Cancer Ther 2013; 4: 367-76.

10. de Gomes SA, Araujo NA, Flichman D, Campos R, Panduro A. Hepatitis B viruses. In: Ludert JE, Pujol FH, Arbiza J (Eds.). Human Virology in Latin America. From Biology to Control. Switzerland, Springer: 2017; p. 309-31.

11. Jose-Abrego A, Panduro A, Fierro NA, Roman S. High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status. J Med Virol 2017; 89: 2149-57.